SightGlass Vision: New 18-Month Data Reinforce DOT Lens Effectiveness
New 18-month clinical data presented by SightGlass Vision at the American Academy of Optometry 2025 annual meeting show that more than half of children wearing DOT spectacle lenses experienced no clinically meaningful myopia progression—nearly 4 times the rate seen in children wearing standard single-vision lenses.[1]
SightGlass Vision’s Diffusion Optics Technology (DOT) approach softly scatters light before it reaches the retina, helping to reduce the visual contrast signals believed to stimulate myopia progression.[2]
The new data, presented by Jennifer Hill, titled "Control of myopia using contrast modulation spectacle lenses in a Chinese population: 18-month results," shares interim outcomes from an ongoing study conducted at five hospitals in China.
Building on earlier 12-month findings, which showed that DOT 0.2 lenses slowed myopia progression by up to 75%, the 18-month data demonstrated that:
57% of children wearing DOT lenses had no clinically meaningful myopia progression, compared to just 15% of children in the control group.[1]
Axial length elongation was 0.34 mm less, and cycloplegic spherical equivalent refraction progression was 0.70 D less among DOT lens wearers compared to controls.[1]
Further reinforcing these findings, Dr. Kylvin Ho of CU Vision in British Columbia presented 2-year real-world effectiveness of myopia control contrast modulation spectacle lenses in a Canadian practice. The data, primarily from Asian Canadian children, highlight DOT lenses’ performance in everyday clinical settings:
Stable refraction (≤0.50 D change) was observed in 52% of younger children (ages 6–7) and 62% of older children (ages 8–10)
Across the practice, DOT lenses slowed myopia progression by at least half on average[4]
Dr. Debbie Laughton presented additional findings exploring whether DOT lenses affect astigmatism development. Results from both North American and Chinese 12-month studies showed no increase in astigmatism among DOT lens wearers compared with control groups.[5]
In North America, the proportion of children with astigmatism changed from 87% to 92%, while in China it shifted from 91% to 88%—both comparable to control groups
“The data confirm that DOT lenses slow myopic progression without influencing astigmatic outcomes,” Dr. Laughton said.
Additional research on subfoveal choroidal thickening across contrast-, defocus-modulating, and standard lenses will also be presented at Academy ’25.
A podium education session led by Drs. Debbie Jones, Jill Woods, and Ashley Tucker, developed in collaboration with SightGlass Vision, will take place on October 9 at 1:30 p.m. in Room 205 ABC, focusing on comparative research across spectacle lens designs and providing clinical guidance for myopia management. Other SightGlass Vision sessions will be held in the Exhibit Hall (4:30–6:30 p.m.) on the same day.
References
Hill J. Control of myopia using contrast modulation spectacle lenses in a Chinese population: 18-month results. Presented at the American Academy of Optometry Annual Meeting, 2025.
SightGlass Vision. Diffusion Optics Technology™ overview.
ACUITY 12-month data. SightGlass Vision internal data, 2024.
Ho K. Two-year real-world effectiveness of myopia control contrast modulation spectacle lenses in a Canadian practice. Academy ’25.
Laughton D. Astigmatism findings from North American and Chinese DOT lens studies. Academy ’25.